Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $18.9 million.

  • 4D Molecular Therapeutics' Accumulated Expenses rose 12.95% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 12.95%. This contributed to the annual value of $18.9 million for FY2024, which is 57.06% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Accumulated Expenses stood at $18.9 million, which was up 57.06% from $12.0 million recorded in FY2023.
  • 4D Molecular Therapeutics' 5-year Accumulated Expenses high stood at $18.9 million for FY2024, and its period low was $7.7 million during FY2021.
  • For the 3-year period, 4D Molecular Therapeutics' Accumulated Expenses averaged around $13.3 million, with its median value being $12.0 million (2023).
  • Per our database at Business Quant, 4D Molecular Therapeutics' Accumulated Expenses dropped by 7.49% in 2021 and then soared by 57.06% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Accumulated Expenses (Yearly) stood at $8.4 million in 2020, then decreased by 7.49% to $7.7 million in 2021, then increased by 14.54% to $8.9 million in 2022, then soared by 35.45% to $12.0 million in 2023, then skyrocketed by 57.06% to $18.9 million in 2024.